Your browser doesn't support javascript.
loading
Safety and efficacy of targeted-dose busulfan and bortezomib as a conditioning regimen for patients with relapsed multiple myeloma undergoing a second autologous blood progenitor cell transplantation.
Freytes, César O; Toro, Juan J; Yeh, Rosa F; Stadtmauer, Edward A; Ratanatharathorn, Voravit; Akpek, Görgün; Sahovic, Entezam; Tricot, Guido J; Shaughnessy, Paul J; White, Darrell J; Rodriguez, Tulio E; Solomon, Scott R; Yu, Louie H; Zhao, Cathy; Patil, Shiva; Armstrong, Elizabeth; Smith, Angela; Elekes, Agnes; Kato, Kazunobu; Reece, Donna E.
Afiliação
  • Freytes CO; South Texas Veterans Health Care System, University of Texas Health Science Center at San Antonio, San Antonio, Texas. Electronic address: cesar.freytes@va.gov.
  • Toro JJ; South Texas Veterans Health Care System, University of Texas Health Science Center at San Antonio, San Antonio, Texas.
  • Yeh RF; Seattle Cancer Care Alliance, Fred Hutchinson Cancer Research Center, Seattle, Washington.
  • Stadtmauer EA; Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania.
  • Ratanatharathorn V; Bone Marrow Transplantation, Karmanos Cancer Institute, Detroit, Michigan.
  • Akpek G; Department of Medical Oncology, Marlene and Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland.
  • Sahovic E; Hematology/Oncology, Western Pennsylvania Hospital, Pittsburgh, Pennsylvania.
  • Tricot GJ; Division of Hematology/BMT and Myeloma Program, Department of Internal Medicine - Hematology, University of Utah School of Medicine, Salt Lake City, Utah.
  • Shaughnessy PJ; Texas Transplant Institute, San Antonio, Texas.
  • White DJ; Division of Hematology, Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada.
  • Rodriguez TE; Cardinal Bernardin Cancer Center, Loyola University Chicago Medical Center, Maywood, Illinois.
  • Solomon SR; The Blood and Marrow Transplant Program, Northside Hospital, Atlanta, Georgia.
  • Yu LH; Seattle Cancer Care Alliance, Fred Hutchinson Cancer Research Center, Seattle, Washington.
  • Zhao C; Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, New Jersey.
  • Patil S; Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, New Jersey.
  • Armstrong E; Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, New Jersey.
  • Smith A; Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, New Jersey.
  • Elekes A; Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, New Jersey.
  • Kato K; Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, New Jersey.
  • Reece DE; Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, Ontario, Canada.
Biol Blood Marrow Transplant ; 20(12): 1949-57, 2014 Dec.
Article em En | MEDLINE | ID: mdl-25139216
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pirazinas / Ácidos Borônicos / Bussulfano / Transplante de Células-Tronco Hematopoéticas / Condicionamento Pré-Transplante / Agonistas Mieloablativos / Mieloma Múltiplo / Antineoplásicos Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies Idioma: En Revista: Biol Blood Marrow Transplant Assunto da revista: HEMATOLOGIA / TRANSPLANTE Ano de publicação: 2014 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pirazinas / Ácidos Borônicos / Bussulfano / Transplante de Células-Tronco Hematopoéticas / Condicionamento Pré-Transplante / Agonistas Mieloablativos / Mieloma Múltiplo / Antineoplásicos Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies Idioma: En Revista: Biol Blood Marrow Transplant Assunto da revista: HEMATOLOGIA / TRANSPLANTE Ano de publicação: 2014 Tipo de documento: Article